ARIX.L Regulatory News (ARIX)

ARIX.L Information

There is currently no data for ARIX

Results of Annual General Meeting

14 Jun 2021 14:55

Arix Bioscience PLC (ARIX) Results of Annual General Meeting 14-Jun-2021 / 14:55 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

Arix Bioscience Plc

Results of Annual General Meeting

LONDON, 14 June 2021: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or the "Company"), a global venture capital company focused on investing and building breakthrough biotech companies, today announces that its Annual General Meeting (the "Meeting") was held today, Monday, 14 June 2021, at 14.00 BST. At the Meeting, the ordinary and special resolutions set out in the Notice of the Annual General Meeting dated 18 May 2021 (the "Notice of AGM"), were proposed and passed by way of a poll. Resolutions 1 to 10 were passed as ordinary resolutions. Resolutions 11 to 14 were passed as special resolutions.

Full details of the poll results are set out below and will also be available on the Company's website.

No	RESOLUTION	VOTES FOR	%	VOTES AGAINST	%	TOTAL VOTES	% of ISC VOTED	VOTES WITHHELD
1	To receive the Directors' Report and the accounts of the Company for the year ended 31 December 2020	61,517,202	92.76%	4,800,657	7.24%	66,317,859	50.32	2,783
2	To approve the Directors' Remuneration Report	58,196,535	92.34%	4,825,953	7.66%	63,022,488	47.82	3,298,154
3	To re-elect Giles Kerr as a Director	61,344,286	92.51%	4,964,902	7.49%	66,309,188	50.31	11,454
4	To elect Peregrine Moncreiffe as a Director	60,271,773	92.55%	4,855,144	7.45%	65,126,917	49.42	1,193,725
5	To elect Maureen O'Connell as a Director	58,841,750	90.36%	6,274,013	9.64%	65,115,763	49.41	1,204,879
6	To elect Isaac Kohlberg as a Director	58,842,050	90.35%	6,285,167	9.65%	65,127,217	49.42	1,193,425
7	To elect Robert Lyne as a Director	60,072,787	90.59%	6,236,701	9.41%	66,309,488	50.31	11,154
8	To appoint BDO LLP as auditors of the Company	61,500,167	92.74%	4,817,701	7.26%	66,317,868	50.32	2,774
9	To authorise the Audit and Risk Committee of the Company to fix the remuneration of the auditors	61,516,153	92.76%	4,804,189	7.24%	66,320,342	50.32	300
10	To authorise the Directors to allot shares	61,019,094	92.01%	5,297,239	7.99%	66,316,333	50.32	4,309
11	Authority to disapply statutory pre‐ emption rights*	59,364,402	89.52%	6,951,931	10.48%	66,316,333	50.32	4,309
12	Additional authority to disapply statutory pre‐ emption rights*	59,363,555	89.52%	6,952,778	10.48%	66,316,333	50.32	4,309
13	To authorise the Company to purchase its own shares*	61,478,596	92.71%	4,836,857	7.29%	66,315,453	50.32	5,189
14	Authority to call a general meeting, other than an annual general meeting, on not less than 14 clear days' notice*	61,517,295	92.76%	4,803,047	7.24%	66,320,342	50.32	300

*Special resolutions

In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

The full text of the resolutions considered at the AGM are contained in the Notice of AGM, published on 18 May 2021, which is available on Arix investor relations website.

A replay of the presentation and the Meeting will be available via webcast shortly after the event on the Company's investor relations website at: https://arixbioscience.com/investor-relations/events-presentations

[ENDS]

For more information on Arix, please contact:

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

charlotte@arixbioscience.com

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Shabnam Bashir

+44 (0)20 3922 1906

optimum.arix@optimumcomms.com

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com


ISIN:	GB00BD045071
Category Code:	RAG
TIDM:	ARIX
LEI Code:	213800OVT3AHQCXNIX43
OAM Categories:	3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:	111187
EQS News ID:	1207766


End of Announcement	EQS News Service

UK Regulatory announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date		Source	Headline
28th May 2021	4:56 pm	EQS	Transaction in own shares
27th May 2021	4:58 pm	EQS	Transaction in own shares
26th May 2021	4:53 pm	EQS	Transaction in own shares
25th May 2021	5:24 pm	EQS	Transaction in own shares
24th May 2021	5:04 pm	EQS	Transaction in own shares
21st May 2021	5:09 pm	EQS	Transaction in own shares
20th May 2021	5:27 pm	EQS	Transaction in own shares
20th May 2021	7:00 am	EQS	Change of registered office
19th May 2021	5:06 pm	EQS	Transaction in own shares
18th May 2021	5:33 pm	EQS	Transaction in own shares
18th May 2021	7:00 am	EQS	Notice of 2021 Annual General Meeting
17th May 2021	5:40 pm	EQS	Transaction in own shares
14th May 2021	5:02 pm	EQS	Transaction in own shares
13th May 2021	5:16 pm	EQS	Transaction in own shares
12th May 2021	5:12 pm	EQS	Transaction in own shares
12th May 2021	4:35 pm	EQS	Autolus to present additional data in AUTO1 in IBCL
11th May 2021	5:43 pm	EQS	Transaction in own shares
10th May 2021	5:21 pm	EQS	Transaction in own shares
7th May 2021	5:19 pm	EQS	Transaction in own shares
6th May 2021	5:23 pm	EQS	Transaction in own shares
5th May 2021	5:16 pm	EQS	Transaction in own shares
4th May 2021	5:15 pm	EQS	Transaction in own shares
4th May 2021	7:00 am	EQS	Total Voting Rights
30th Apr 2021	4:59 pm	EQS	Transaction in own shares
30th Apr 2021	7:00 am	EQS	Outcome of Strategic Implementation Review and Directorate Change
29th Apr 2021	5:10 pm	EQS	Transaction in own shares
28th Apr 2021	5:14 pm	EQS	Transaction in own shares
28th Apr 2021	12:02 pm	EQS	Amplyx Pharmaceuticals acquired by Pfizer
27th Apr 2021	5:29 pm	EQS	Transaction in own shares
27th Apr 2021	2:00 pm	EQS	LogicBio announces clinical and corporate updates
26th Apr 2021	5:32 pm	EQS	Transaction in own shares
23rd Apr 2021	5:11 pm	EQS	Transaction in own shares
22nd Apr 2021	5:15 pm	EQS	Transaction in own shares
21st Apr 2021	5:27 pm	EQS	Transaction in own shares
20th Apr 2021	5:31 pm	EQS	Transaction in own shares
19th Apr 2021	5:09 pm	EQS	Transaction in own shares
16th Apr 2021	5:18 pm	EQS	Transaction in own shares
15th Apr 2021	5:09 pm	EQS	Transaction in own shares
14th Apr 2021	5:13 pm	EQS	Transaction in own shares
13th Apr 2021	5:13 pm	EQS	Transaction in own shares
12th Apr 2021	5:23 pm	EQS	Transaction in own shares
9th Apr 2021	5:44 pm	EQS	Transaction in own shares
8th Apr 2021	5:28 pm	EQS	Transaction in own shares
8th Apr 2021	8:19 am	RNS	Proactive One2One Virtual Investor Forum
8th Apr 2021	7:00 am	EQS	Arix to Present at the Proactive One2One Virtual Investor Forum
7th Apr 2021	5:47 pm	EQS	Transaction in own shares
7th Apr 2021	7:00 am	EQS	Artios announces collaboration with Novartis to create next generation DDR cancer therapies
6th Apr 2021	5:26 pm	EQS	Transaction in own shares
1st Apr 2021	5:20 pm	EQS	Transaction in own shares
1st Apr 2021	7:00 am	EQS	Total Voting Rights

Latest Share Chat

ARIX.L Regulatory News (ARIX)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of Annual General Meeting

Login to your account

Quickpicks are a member only feature

Login to your account